We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
BusinessFinanceSpecialties

Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials

Deanna Pogorelc
Deanna Pogorelc
Share
4 Min Read
SHARE

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials.

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials. For startup Alzheon, though, those failures have left behind a trail of valuable clinical and biomarker data that it thinks could lead to hidden treasure.

Alzheon launched today with a plan to scoop up abandoned drug candidates to which it thinks it can apply recent advances in the understanding of Alzheimer’s disease and new diagnostic and prognostic tools to refine the drugs and target them toward more specific groups of patients.

For its first clinical candidate, the Lexington, Massachusetts-based biotech has licensed a prodrug of the small molecule tramiprosate from Bellus Health (formerly Neurochem Inc.) of Quebec, Canada. It was designed to inhibit the formation of amyloid assemblies in the brain that experts have long considered characteristic of the disease.

More Read

recruiting - recruitment - talent aquisition concept
5 Major Challenges in Healthcare Recruitment Today
Disruptions on the Yellow Brick Road II
Who Owns Frozen Embryos?
Cancer Drugs: Why the High and Rising Prices?
Why US Healthcare Costs So Much More – it’s the Monopoly Factor

In the late 2000s, Neurochem took the drug as far as Phase 3 studies involving more than a thousand Alzheimer’s disease patients. It failed to meet the trial’s efficacy endpoints.

But in a retrospective analysis of clinical data, researchers found that the drug seemed to slow atrophy of the hippocampus, a kind of brain damage associated with Alzheimer’s, especially in patients with a gene variation called APOE4.

Alzheon will piggyback on those clues and use a prodrug form of tramiprosate, or an inactive substance that is converted into an active drug inside the body. CEO Dr. Martin Tolar said the prodrug has better properties than its parent drug.

Tolar is a neurologist by training and spent six years in leadership positions at Pfizer before taking on roles at various smaller biotech companies including CoMentis Inc., NormOxys and Knome Inc. Working with him on this new venture is former CoMentis and NormOxys colleague John Hey, a 20-year drug development veteran, and Dr. Mark Versavel, who has led neurology projects at Bayer and Pfizer.

The team will use their combined science and business savvy and the existing clinical data behind ALZ-801 to design a Phase 2 efficacy study around specific subpopulations of Alzheimer’s patients who stand to benefit most from the drug. Tolar said the trial should start next year.

While smaller, more targeted trials should in theory be quicker and more likely to produce positive results than large trials, the trials will still be costly. Tolar declined to disclose details of his company’s initial financing but said his team is working with two private investors with a history success in biopharmaceuticals.

As plans for the trial get underway, Alzheon, which was incorporated in August, is also at work building a pipeline. Tolar said the team is in talks with other companies about in-licensing deals that would bring in other therapeutic approaches that have demonstrated safety and proof-of-concept activity in neurodegenerative disease.

Chief Scientific Officer Hey summed up the company’s long-term strategy in a statement: “Alzheon has unique capabilities to deploy our drug development platform and leverage the clinical knowledgebase from past Alzheimer’s programs to deliver the best of both worlds:  innovative treatments for challenging neurodegenerative diseases and well-designed clinical programs that have a high likelihood of success.”

Follow MedCity News on Facebook and Twitter for more updates.

[Image credit: BigStock Photos]

TAGGED:AlzheimersAlzheon
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

Image
Radiology

Major Advances in Radiation Therapy Mean Greater Effectiveness, Fewer Side Effects and Less Time in Treatment

April 8, 2012

Increasing Medicare Eligibility Age and the Law of Unintended Consequences

November 8, 2011

Next Generation Not Prepared for Retirement Either

May 26, 2011

Kyruus Brings Big Data to Health Care. Podcast Interview

May 1, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?